JPWO2020263650A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020263650A5 JPWO2020263650A5 JP2021576604A JP2021576604A JPWO2020263650A5 JP WO2020263650 A5 JPWO2020263650 A5 JP WO2020263650A5 JP 2021576604 A JP2021576604 A JP 2021576604A JP 2021576604 A JP2021576604 A JP 2021576604A JP WO2020263650 A5 JPWO2020263650 A5 JP WO2020263650A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- macrophages
- agent
- bone marrow
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867593P | 2019-06-27 | 2019-06-27 | |
| US62/867,593 | 2019-06-27 | ||
| PCT/US2020/038115 WO2020263650A1 (en) | 2019-06-27 | 2020-06-17 | Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022539038A JP2022539038A (ja) | 2022-09-07 |
| JPWO2020263650A5 true JPWO2020263650A5 (pt) | 2023-06-26 |
Family
ID=74060354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576604A Pending JP2022539038A (ja) | 2019-06-27 | 2020-06-17 | 骨髄細胞炎症性表現型を調節するための抗ｌｒｒｃ２５組成物及び方法、ならびにその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220363752A1 (pt) |
| EP (1) | EP3990017A4 (pt) |
| JP (1) | JP2022539038A (pt) |
| KR (1) | KR20220042131A (pt) |
| CN (1) | CN114423452A (pt) |
| AU (1) | AU2020306772A1 (pt) |
| BR (1) | BR112021026411A2 (pt) |
| CA (1) | CA3142838A1 (pt) |
| IL (1) | IL289166A (pt) |
| WO (1) | WO2020263650A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024077170A1 (en) * | 2022-10-05 | 2024-04-11 | Shangpharma Innovation, Inc. | Anti-urokinase-type plasminogen activator receptor antibodies and methods of use |
| CN116380755B (zh) * | 2023-03-20 | 2023-11-21 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101122628B1 (ko) * | 2009-02-16 | 2012-04-12 | 한국화학연구원 | 노닐페놀에 의해 유도된 생식독성 진단용 바이오마커 및 이를 이용한 생식독성 진단 방법 |
| US10279018B2 (en) * | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
| US20190004052A1 (en) * | 2015-06-18 | 2019-01-03 | Thomas Mole Herd | Methods of characterising cancer |
| EP3314020A1 (en) * | 2015-06-29 | 2018-05-02 | The Broad Institute Inc. | Tumor and microenvironment gene expression, compositions of matter and methods of use thereof |
| CN109313201B (zh) * | 2016-06-14 | 2022-04-01 | 高级生物设计公司 | 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体 |
| US20190233534A1 (en) * | 2016-07-14 | 2019-08-01 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| JP2021529753A (ja) * | 2018-06-29 | 2021-11-04 | ヴェルソー セラピューティクス， インコーポレイテッド | 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法 |
-
2020
- 2020-06-17 AU AU2020306772A patent/AU2020306772A1/en not_active Abandoned
- 2020-06-17 BR BR112021026411A patent/BR112021026411A2/pt unknown
- 2020-06-17 US US17/620,264 patent/US20220363752A1/en active Pending
- 2020-06-17 CN CN202080061285.3A patent/CN114423452A/zh active Pending
- 2020-06-17 CA CA3142838A patent/CA3142838A1/en active Pending
- 2020-06-17 JP JP2021576604A patent/JP2022539038A/ja active Pending
- 2020-06-17 EP EP20833200.7A patent/EP3990017A4/en not_active Withdrawn
- 2020-06-17 WO PCT/US2020/038115 patent/WO2020263650A1/en active Application Filing
- 2020-06-17 KR KR1020227003081A patent/KR20220042131A/ko unknown
-
2021
- 2021-12-20 IL IL289166A patent/IL289166A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20180011250A (ko) | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 | |
| US20140242081A1 (en) | Dosing regimens for treatment of cea-expressing cancers | |
| KR20180011251A (ko) | T 세포 요법을 위한 진단 방법 | |
| Gorter et al. | Versican expression is associated with tumor-infiltrating CD8-positive T cells and infiltration depth in cervical cancer | |
| JP6944925B2 (ja) | 組織浸潤ｎｋ細胞を検出する方法 | |
| US20220169694A1 (en) | Chimeric antigen receptor t cell therapy | |
| JP2022527941A (ja) | 光免疫療法のための方法および関連バイオマーカー | |
| CN112703012A (zh) | 治疗癌症的方法 | |
| US11648307B2 (en) | Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy | |
| JP2021500336A (ja) | 抗ｃｄ４７及び抗ｐｄ−ｌ１による卵巣癌の処置 | |
| Rossi et al. | Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2–bispecific antibody is enhanced in combination with interferon-α | |
| JP2022511337A (ja) | 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 | |
| AU2021283714A1 (en) | Treatment of CD30-positive cancer | |
| JPWO2020006385A5 (pt) | ||
| Cole et al. | First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors | |
| US20220016165A1 (en) | Chimeric antigen receptor t cell therapy | |
| JPWO2020247372A5 (pt) | ||
| JPWO2020263650A5 (pt) | ||
| EP3388073A1 (en) | Targeting mesothelin in brain cancer | |
| JPWO2021243169A5 (pt) | ||
| EP4007774A1 (en) | Combined inhibition of semaphorin-4d and tgfb and compositions therefor | |
| Wilczyński et al. | Immunology and Immunotherapy of Ovarian Cancer | |
| JPWO2020247371A5 (pt) | ||
| JPWO2020263651A5 (pt) | ||
| EP3388836B1 (en) | Methods for predicting survival and treatment susceptibility of glioblastoma multiforme (gbm) patients using cytokine profiles |